The following article features coverage from the 2021 American Society of Hematology Annual Meeting. Click here to read more of Cancer Therapy Advisor’s conference coverage.

The chimeric antigen receptor (CAR) T-cell therapy CT103A produced durable responses in patients with relapsed/refractory multiple myeloma (MM), results from a phase 1/2 study suggest. 

CT103A — a fully human, BCMA-specific CAR T-cell therapy — yielded responses even in patients who had received prior murine BCMA CAR T-cell therapy, according to Di Wang, MD, PhD, of Tongji Hospital in Wuhan, China. 

Dr Wang presented these results at the 2021 American Society of Hematology (ASH) Annual Meeting. 


Continue Reading

The phase 1/2 trial included 79 patients with relapsed/refractory MM. At baseline, the patients’ median age was 56 years (range, 39-70 years), 59.5% were men, and 13.9% had extramedullary MM (EMM). 

All patients were refractory to their last treatment. They had received a median of 5 prior lines of therapy (range, 3-13), 26.6% had undergone autologous transplant, and 16.5% had received prior CAR T-cell therapy. 

Patients received the recommended phase 2 dose of CT103A (1.0 x 106 cells/kg) after lymphodepletion with fludarabine and cyclophosphamide. 

For the entire cohort, the objective response rate was 94.9%, and the complete response (CR) rate was 58.2%. Among patients who had EMM and/or had received prior CAR T-cell therapy (n=20), the ORR was 85.0%, and the CR rate was 55.0%. 

In the entire cohort, 93.7% of patients achieved minimal residual disease (MRD) negativity. The median time to MRD negativity was 15.5 days.

The median progression-free survival (PFS) was 25.3 months. The 6-month PFS rate was 78.0%, and the 12-month PFS rate was 71.0%. 

Cytokine release syndrome (CRS) was most commonly grade 1 (64.6%) or grade 2 (27.8%) in severity. There were no cases of grade 4 or 5 CRS, and 2.5% of patients had grade 3 CRS. The median time to CRS onset was 6 days, and the median duration was 5 days. 

There was 1 case of grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS). All cases of CRS and ICANS resolved after intervention.

Disclosures: This research was supported by IASO Therapeutics, Inc. Some study authors declared affiliations, including employment, with IASO Therapeutics. Please see the original reference for a full list of disclosures.

Read more of Cancer Therapy Advisor’s coverage of the ASH 2021 meeting by visiting the conference page.

Reference

Li C, Wang D, Song Y, et al. A phase 1/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and/or refractory multiple myeloma. Presented at ASH 2021; December 11-14, 2021. Abstract 547.